169 related articles for article (PubMed ID: 27436851)
1. Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.
Burley K; Whyte CS; Westbury SK; Walker M; Stirrups KE; Turro E; ; Chapman OG; Reilly-Stitt C; Mutch NJ; Mumford AD
Blood; 2016 Oct; 128(14):1879-1883. PubMed ID: 27436851
[TBL] [Abstract][Full Text] [Related]
2. A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.
Westbury SK; Whyte CS; Stephens J; Downes K; Turro E; Claesen K; Mertens JC; Hendriks D; Latif AL; Leishman EJ; ; Mutch NJ; Tait RC; Mumford AD
J Thromb Haemost; 2020 Sep; 18(9):2209-2214. PubMed ID: 32634856
[TBL] [Abstract][Full Text] [Related]
3. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis.
Dai L; Mitchell M; Savidge G; Alhaq A
J Thromb Haemost; 2004 Dec; 2(12):2200-4. PubMed ID: 15613027
[TBL] [Abstract][Full Text] [Related]
4. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
Bajzar L; Nesheim M; Morser J; Tracy PB
J Biol Chem; 1998 Jan; 273(5):2792-8. PubMed ID: 9446587
[TBL] [Abstract][Full Text] [Related]
5. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
Mosnier LO
J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
[TBL] [Abstract][Full Text] [Related]
6. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
[TBL] [Abstract][Full Text] [Related]
7. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.
Mosnier LO; Elisen MG; Bouma BN; Meijers JC
Thromb Haemost; 2001 Oct; 86(4):1057-64. PubMed ID: 11686324
[TBL] [Abstract][Full Text] [Related]
8. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
[TBL] [Abstract][Full Text] [Related]
9. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
Marar TT; Boffa MB
J Thromb Haemost; 2016 Apr; 14(4):772-83. PubMed ID: 26816270
[TBL] [Abstract][Full Text] [Related]
10. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
11. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.
Bajzar L; Morser J; Nesheim M
J Biol Chem; 1996 Jul; 271(28):16603-8. PubMed ID: 8663147
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
13. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype.
Morrow GB; Beavis J; Harper S; Bignell P; Laffan MA; Curry N
Thromb Res; 2021 Jan; 197():100-108. PubMed ID: 33190022
[TBL] [Abstract][Full Text] [Related]
15. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Jan; 85(1):5-11. PubMed ID: 11204587
[TBL] [Abstract][Full Text] [Related]
16. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
Wu C; Stafford AR; Fredenburgh JC; Weitz JI; Gils A; Declerck PJ; Kim PY
Thromb Haemost; 2017 Jul; 117(8):1509-1517. PubMed ID: 28640323
[TBL] [Abstract][Full Text] [Related]
17. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.
Wu C; Kim PY; Swystun LL; Liaw PC; Weitz JI
J Thromb Haemost; 2016 Feb; 14(2):366-74. PubMed ID: 26663133
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Taketomi T; Szlam F; Bader SO; Sheppard CA; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):135-41. PubMed ID: 18277134
[TBL] [Abstract][Full Text] [Related]
19. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
[TBL] [Abstract][Full Text] [Related]
20. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Higuchi T; Nakamura T; Kakutani H; Ishii H
Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
